Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that a new questionnaire to assess mental health in alopecia patients shows low rates of seeking mental health services and support groups.

The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.

SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe symptoms and organ damage in mice.

New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.

The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.

The Polish Skindex-29 is a reliable and valid questionnaire for assessing the quality of life in Polish dermatology patients.

The HAIR-Q is a reliable tool for assessing patient satisfaction with hair loss treatments.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.

The document sets criteria for diagnosing long-term sexual dysfunctions caused by certain medications.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

The Swedish Hairdex-S is a reliable tool for assessing quality of life in Alopecia Areata patients.

The Spanish Hair-Specific Skindex-29 questionnaire effectively measures the quality of life impact of hair loss in Spanish-speaking women.

SII is a useful and affordable tool to assess and monitor alopecia areata.

Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Using both DLQI and Skindex-16 together gives a better understanding of quality of life in skin disease patients.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

The Turkish version of the MAIA-2 Scale is valid and reliable for patients at a dermatology clinic.

The updated SALT II tool offers a more precise way to measure scalp hair loss.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.

Ritlecitinib is safe and may effectively treat alopecia areata.